Can helicobacter pylori infection reduce the risk of Multiple sclerosis? A systematic review and meta-analysis

Volume 2, Issue 2, July 2023, Pages 97-105

10.61186/nl.2.2.97

Fardin Nabizadeh; Nazanin Rafiei; Seyedeh Maryam Vafaei; Mobin Azami; kimia rasouli; Elham Moases Ghaffary; Omid Mirmosayyeb

• View Article
• PDF 1.87 M

---

Escalation or high-efficacy disease-modifying therapies in multiple sclerosis

Volume 2, Issue 2, July 2023, Pages 106-108

10.61186/nl.2.2.106

Elnaz Asadollahzadeh

• View Article
• PDF 1.15 M

---

Personalized Treatment for Multiple Sclerosis: The Role of Precision Medicine

Volume 2, Issue 1, April 2023, Pages 30-34

10.52547/nl.2.1.30

Lokesh Pathak

• View Article
• PDF 1.02 M

---

Optical Coherence Tomography (OCT) Measurements and Disability in Multiple Sclerosis (MS): Protocol of Systematic Review

Volume 2, Issue 1, April 2023, Pages 44-46

10.52547/nl.2.1.44

Omid Mirmosayyeb; Elham Moases Ghaffary

• View Article
• PDF 1.06 M

---

Neuroinflammation and Neurodegenerative disease

Volume 1, Issue 1, June 2022, Pages 19-20

10.52547/nl.1.1.19

Maedeh Khodkam

• View Article
• PDF 988.9 K

---

Helicobacter Pylori specific antibodies among multiple sclerosis patients

Volume 1, Issue 1, June 2022, Pages 28-31

10.52547/nl.1.1.28

Seyed-Amirabbas Ahadiat; Seyed-Ali Masoud; Mohammad sadegh khorshidi; Zeinab Hosseinian; Alireza Namvari

• View Article
• PDF 1.3 M

---

Acute relapse of Multiple Sclerosis (MS) in an adolescent patient after Tuberculin skin test (TST): a case report

Volume 1, Issue 1, June 2022, Pages 34-36

10.52547/nl.1.1.34

Kasra Pirahesh; Aria Motamedi-Jahromi

• View Article
• PDF 1.12 M

---